X4 Pharmaceuticals, Inc (XFOR) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.51

From 52W high−23.34%

Volume1.54M

Market cap$354.95M

P/E (TTM)—

P/S (TTM)22.4x

Div yield—

Key dataSep 18, 2026

Open

$3.51

From 52W high

−23.34%

Volume

1.54M

Market cap

$354.95M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.8x

P/E (TTM)

—

RSI (14)

40.4

MomentumView details →

1D Return

+2.29%

YTD Return

−10.25%

SummaryUpdated Jun 1, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a late-stage clinical biopharmaceutical company founded in 2010 and headquartered in Boston, Massachusetts. The company went public in November 2017 and focuses on developing novel therapeutics for rare diseases. X4 Pharmaceuticals achieved a significant milestone in 2024 with the FDA approval and commercial launch of its lead drug XOLREMDI (mavorixafor) for WHIM syndrome, marking its transition from a pure development-stage company to a commercial-stage biopharmaceutical enterprise.

Ask drillr about X4 Pharmaceuticals, Inc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.8x

EV/Sales

14.1x

P/S (TTM)

22.4x

P/B (TTM)

2.3x

ProfitabilityView details →

Gross Margin

81.22%

Net Margin

−568.80%

EBITDA Margin

−501.82%

ROE (TTM)

−57.98%

ROA (TTM)

−35.62%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

−51.65%

EPS YoY

+91.91%

FCF YoY

—

Revenue CAGR 3Y

+1273.21%

EPS CAGR 3Y

+66.55%

EBITDA YoY

+12.69%

MomentumView details →

1D Return

+2.29%

YTD Return

−10.25%

1Y Return

+13.25%

RSI (14)

40.4

vs 50D SMA

−9.76%

vs 200D SMA

−8.78%

Capital & dividendView details →

Debt/Equity

0.50x

Current Ratio

11.30x

Quick Ratio

11.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.13

EPS Surprise

26.14%

Beats (12Q)

8/12

Next Q EPS Est

−$0.18

Avg Surprise (4Q)

19.52%

Rev Surprise

263.88%

Financials snapshotView financials →

Revenue (TTM)

15.85M

Net Income (TTM)

−90.14M

Op. CF (TTM)

−83.74M

Next earningsNov 4, 2026 →

Latest newsMore news →

X4 Pharmaceuticals reported financial results for the second quarter ended June 30, 2026.45d ago

X4 Pharmaceuticals appointed Kelly Gold to its Board of Directors as an independent director and member of the Audit Committee, effective July 1, 2026.81d ago

Similar companies

Enanta Pharmaceuticals, Inc.ENTA Agenus Inc.AGEN Shanghai Bio-heart Biological Technology Co., Ltd.02185.HK Sirnaomics Ltd.02257.HK Alpha Tau Medical Ltd.DRTSW Ocugen, Inc.OCGN Find similar companies →

Latest newsMore news →

X4 Pharmaceuticals reported financial results for the second quarter ended June 30, 2026.45d ago X4 Pharmaceuticals appointed Kelly Gold to its Board of Directors as an independent director and member of the Audit Committee, effective July 1, 2026.81d ago